{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.72","upperLimit":"8.08","value":"6.67"},{"groupId":"OG001","lowerLimit":"7.16","upperLimit":"12.68","value":"9.63"},{"groupId":"OG002","lowerLimit":"4.27","upperLimit":"6.80","value":"5.29"},{"groupId":"OG003","lowerLimit":"5.75","upperLimit":"9.56","value":"7.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"111"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"Disease that can be assessed clinically (physical examination) should be evaluated every cycle (every 3 weeks). Disease assessed by imaging modalities (CXR, CT, MRI) should be evaluated every other cycle unless other evidence of a change mandates earlier assessment. Tumor measurements should also be done after the final cycle (if the patient is taken off of study therapy for a reason other than progression) and then every 3 months x 2 years (followed with every 6 months x 3 years) until progression is documented. \"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions assessed radiographically and 50% increase if the only target lesion is a solitary pelvic mass measured by physical exam, or unequivocal progression of a non-target lesion, or the appearance of new lesions\", or similar definition as accurate and appropriate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity","id":"OG000","title":"Arm I (Paclitaxel and Cisplatin)"},{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG001","title":"Arm II (Paclitaxel, Cisplatin, Bevacizumab)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity","id":"OG002","title":"Arm III (Topotecan Hydrochloride and Paclitaxel)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG003","title":"Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)"}],"paramType":"MEDIAN","populationDescription":"All randomized patients.","reportingStatus":"POSTED","timeFrame":"From study entry until disease progression, death or date of last contact, assessed up to 5 years (During treatment: every 3 weeks if by physical exam, every 6 weeks by CXR, CT or MRI. In follow-up: quarterly for 2 years then semi-annually for 3 years)","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}